Search ↗

Comparison

Gonadorelin vs Kisspeptin-10

Both are reproductive & HPTA, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Gonadorelin is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

Gonadorelin Kisspeptin-10
Class Reproductive & HPTA Reproductive & HPTA
Evidence Regulator approved Clinical trials
Human trials ~30 ~25
Half-life ~2-10 minutes ~4 minutes
Reported range 100-200 mcg 10-100 mcg
Frequency 2-3x weekly, or more frequently in fertility protocols Research protocols vary widely
Routes Subcutaneous, Intramuscular Subcutaneous, Intramuscular
FDA approved Yes No
Research use only No Yes
Banned in sport Yes No
Studied for Preservation of testicular function during TRT, Hypogonadotropic hypogonadism, Fertility Reproductive axis research, Fertility research, Sexual desire research
Reported side effects Injection-site reactions, Headache, Flushing, Nausea Flushing, Injection-site reactions, Headache

Gonadorelin

Gonadorelin is identical to endogenous gonadotropin-releasing hormone, a decapeptide secreted in pulses by the hypothalamus. Pulsatile delivery stimulates pituitary release of LH and FSH, maintaining testicular steroidogenesis and spermatogenesis. The pharmacology is strictly pulse-dependent: continuous exposure downregulates the receptor and suppresses gonadotropins instead, which is how GnRH agonists are used for chemical castration. Its very short half-life is the reason frequent dosing is required.

Kisspeptin-10

Kisspeptin-10 is the shortest active fragment of kisspeptin, the peptide encoded by KISS1 that acts at the KISS1R receptor on hypothalamic GnRH neurons. It sits one level above GnRH in the reproductive hierarchy and is the principal gatekeeper of puberty and fertility, integrating metabolic and hormonal signals. Because it stimulates endogenous pulsatile GnRH rather than replacing it, research interest centres on inducing more physiological LH release than direct GnRH dosing achieves.

Gonadorelin vs Kisspeptin-10: common questions

What is the difference between Gonadorelin and Kisspeptin-10?

Both are reproductive & HPTA. Gonadorelin: Synthetic gonadotropin-releasing hormone, increasingly used alongside TRT to maintain testicular function. Kisspeptin-10: The upstream trigger for GnRH release, and the most physiologically natural way to stimulate the reproductive axis.

Which has stronger evidence, Gonadorelin or Kisspeptin-10?

Gonadorelin has the stronger evidence base (regulator approved, about 30 human studies) compared with Kisspeptin-10 (clinical trials).

Are Gonadorelin and Kisspeptin-10 FDA approved?

Only Gonadorelin is FDA approved (Evaluation of hypothalamic-pituitary-gonadal function (US marketing discontinued)). Kisspeptin-10 is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 638793) ↗ · structure, identifiers, synonyms
  2. DailyMed: FDA-approved labeling for Gonadorelin ↗ · indications, dosing, warnings as approved
  3. FDA Drugs@FDA database ↗ · approval history
  4. WADA Prohibited List ↗ · current year
  5. CAS Registry Number 33515-09-2 ↗ · chemical identity
  6. PubChem compound record (CID 25240297) ↗ · structure, identifiers, synonyms
  7. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  8. CAS Registry Number 374675-21-5 ↗ · chemical identity

Published literature

  1. van Leusden HA. The flush revisited.Eur J Obstet Gynecol Reprod Biol 1994.PubMed 7713285 · doi:10.1016/0028-2243(94)90289-5
  2. Kyriazis I, Bellos T, Katsimperis S, et al.. Relugolix in treatment of prostate cancer: a review.Arch Ital Urol Androl 2025.PubMed 41247145 · doi:10.4081/aiua.2025.14277
  3. Florio S, Pagnini U, Crispino A, et al.. GnRH and steroids in cancer.Front Biosci 2002.PubMed 12045004 · doi:10.2741/A864
  4. Schwanzel-Fukuda M, Zheng LM, Bergen H, et al.. LHRH neurons: functions and development.Prog Brain Res 1992.PubMed 1480748 · doi:10.1016/s0079-6123(08)64572-0
  5. Armer RE, Smelt KH. Non-peptidic GnRH receptor antagonists.Curr Med Chem 2004.PubMed 15544487 · doi:10.2174/0929867043363983
  6. Dellis A, Papatsoris A. Therapeutic outcomes of the LHRH antagonists.Expert Rev Pharmacoecon Outcomes Res 2017.PubMed 28870102 · doi:10.1080/14737167.2017.1375855
  7. Pace JN, Miller JL, Rose LI. GnRH agonists: gonadorelin, leuprolide and nafarelin.Am Fam Physician 1991.PubMed 1835275
  8. Barbieri RL. Endometriosis 1990. Current treatment approaches.Drugs 1990.PubMed 2190793 · doi:10.2165/00003495-199039040-00003
  9. Tena-Sempere M. GPR54 and kisspeptin in reproduction.Hum Reprod Update 2006.PubMed 16731583 · doi:10.1093/humupd/dml023
  10. Ulasov IV, Borovjagin AV, Timashev P, et al.. KISS1 in breast cancer progression and autophagy.Cancer Metastasis Rev 2019.PubMed 31705228 · doi:10.1007/s10555-019-09814-4
  11. Watanabe T, Sato K. Roles of the kisspeptin/GPR54 system in pathomechanisms of atherosclerosis.Nutr Metab Cardiovasc Dis 2020.PubMed 32409274 · doi:10.1016/j.numecd.2020.02.017
  12. Garcia JP, Keen KL, Seminara SB, et al.. Role of Kisspeptin and NKB in Puberty in Nonhuman Primates: Sex Differences.Semin Reprod Med 2019.PubMed 31847024 · doi:10.1055/s-0039-3400253
  13. Arai AC. The role of kisspeptin and GPR54 in the hippocampus.Peptides 2009.PubMed 18765263 · doi:10.1016/j.peptides.2008.07.023
  14. Pastor FM, Santos BR, Silva JF, et al.. Endocrine-metabolic effects of kisspeptin in mammals.Gen Comp Endocrinol 2026.PubMed 41581529 · doi:10.1016/j.ygcen.2026.114888
  15. Prabhu VV, Sakthivel KM, Guruvayoorappan C. Kisspeptins (KiSS-1): essential players in suppressing tumor metastasis.Asian Pac J Cancer Prev 2013.PubMed 24377507 · doi:10.7314/apjcp.2013.14.11.6215
  16. Makri A, Pissimissis N, Lembessis P, et al.. The kisspeptin (KiSS-1)/GPR54 system in cancer biology.Cancer Treat Rev 2008.PubMed 18583061 · doi:10.1016/j.ctrv.2008.05.007

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.